About Us

Biocytogen: Innovative Models to Empower Antibody Discovery

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with top pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

 

 

Our Missions

  • Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
  • Develop technological platforms to accelerate next-generation drug discovery and development
  • Empower scientists in drug discovery by providing the necessary expertise to eliminate bottlenecks in research
  • Be a global leader in providing seamless preclinical services to our clients

Our Milestones

2021.6

Completed a new round of financing totaling tens of millions of dollars.

2020.9

Completion of D+ round financing, enabling progression of the RenMice HiTS Platform initiative.

2020.8

Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.

2020.5

Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China

2020.3

RenMice HiTS Platform initiative launched, signifying Biocytogen’s transformation to a biotechnology company

2020.1

Anti-OX40 antibody YH002 was approved for clinical trials in the United States

2019.10

Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States

2019.8

Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July

2019.4

Beijing and Haimen Phase II animal facility is under construction

2018.4

Received C-round funding from CMB International Capital Corporation Limited, SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings

2018.2

Boston and Shanghai sites opened for business

2016

Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients

2015

Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund

2014

Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model

2011

1st customized gene targeted mouse line delivered

2009

Beijng Biocytogen Co., Ltd (Headquarters) established

2008

Founded in Worcester, MA, USA

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1

Programmed death-ligand 1 is a glycoprotein expressed on antigen presenting cells, hepatocytes, and tumors which upon interaction with programmed death-1, results in inhibition of antigen-specific T cell responses. Here, we…

Read More

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human…

Read More
Back to top